Advertisement

Document › Details
Sirion Biotech GmbH. (1/7/21). "Press Release: Sirion Biotech GmbH Licensed Its LentiBoost Transduction Technology to Cellectis". Munich & Cambridge, MA.
Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™. This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. SIRION is entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sales plus license fees tied to commercial success.
Allogeneic CAR-T cell therapy represent a future-defining shift in simplicity, availability, and cost efficiency of immune-oncology approaches. Engineering effective allogeneic T-cells, in contrast to patient derived cells, elevates the technology to the level of a realistic off-the-shelf product.
Dr. Christian Thirion, CEO and founder of SIRION explains: “LentiBOOST™ improves lentiviral transduction of difficult cell types like hematopoietic stem cells, and in addition generates stable integration of large constructs generally needed to generate CAR-T cells.”
“We are delighted that our product will help further develop affordable allogeneic cancer treatments that will, once approved, benefit patients with unmet needs,” says SVP BD & Licensing, Dr. Sabine Ott.
About SIRION Biotech
SIRION Biotech began its customer business in 2007 in Munich, setting their goal to spark a new generation of viral vector technologies for gene and cell therapy as well as vaccination development. This meant building novel, all-encompassing viral vector platforms for lenti-, adeno-, and adeno-associated viruses which expedite its partners’ advances in drug, cosmetics, and food industries. To date SIRION has completed over 1500 projects of all sizes, working closely with over 200 independent customer groups from academia and industry.
Contacts
Corporate Contact
Dieter Lingelbach, COO
SIRION Biotech
+49 89-700-96199-14
[email protected]
Media Contact USA
Lisa DeScenza
Vice President, Integrated Communications
LaVoieHealthScience
(978) 395-5970
[email protected]
BD & Licensing Contact
Sabine Ott, Ph.D., Senior VP Licensing & BD
SIRION Biotech
+49 89-700-96199-13
[email protected]
Record changed: 2023-06-05 |
Advertisement

More documents for PerkinElmer (Group)
- [1] CN Bio Innovations Ltd.. (3/14/23). "Press Release: CN Bio Appoints Deepak Singh as Vice President of Sales and Marketing". Cambridge....
- [2] CN Bio Innovations Ltd.. (12/19/22). "Press Release: CN Bio Appoints Dr Paul Brooks as Chief Executive Officer". Cambridge....
- [3] PerkinElmer, Inc.. (6/22/21). "Press Release: PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader Sirion Biotech". Waltham, MA....
- [4] PerkinElmer, Inc.. (5/17/21). "Press Release: PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC". Waltham, MA....
- [5] PerkinElmer, Inc.. (5/12/21). "Press Release: PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience". Waltham, MA....
- [6] Congenica Ltd.. (4/6/21). "Press Release: Congenica Appoints Jayesh Pankhania as Chief Financial Officer". Cambridge....
- [7] PerkinElmer, Inc.. (1/7/21). "Press Release: PerkinElmer to Acquire Oxford Immunotec Global plc". Waltham, MA & London....
- [8] PerkinElmer, Inc.. (11/2/20). "Press Release: PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million)". Waltham, MA....
- [9] Sirion Biotech GmbH. (10/6/20). "Press Release: Mustang Bio Licenses LentiBOOST Technology from Sirion Biotech for the Development of MB-207 Lentiviral Gene Therapy". Worcester, MA & Martinsried....
- [10] Rentschler Biopharma SE. (5/19/20). "Press Release: Rentschler Biopharma Licenses Horizon Discovery's CHOSource Platform to Complement Cell Line Development Offering for Difficult-to-Express Proteins". Laupheim, Milford, MA & Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top